2025 Annual Meeting | C29 - MS Across the Lifespan/Pregnancy and Breastfeeding in MS

Date Saturday 04/05/25

Time 02:30 PM - 04:30 PM PDT Add To Calendar

Location San Diego Convention Center | 31C

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Riley Bove, MD, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants should be able to identify the unique counseling and management needs of women during pregnancy, lactation, and menopause; describe the MS disease course during pregnancy and menopause; articulate main safety and ethical considerations around drug choice in women of childbearing potential; summarize principles around drug transfer across the placenta and breastmilk; and apply best practices when caring for women during pregnancy, lactation, and menopause.

CME Available 2.00 CME credits

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
02:30 PM - 02:35 PM PDT	Speaker	Welcome and Introduction: A Lifespan Perspective Riley Bove, MD, FAAN
02:35 PM - 03:10 PM PDT	Speaker	Pregnancy and MS: Bidirectional Relationships, Biology and Treatment Effects Vilija Jokubaitis
03:10 PM - 03:50 PM PDT	Speaker	Immunotherapies during Management of Pregnancy and Breastfeeding Kerstin Hellwig
03:50 PM - 04:30 PM PDT	Speaker	Beyond Pregnancy: Menopause, Gynecological Health, and Healthy Aging Riley Bove, MD, FAAN

Faculty Disclosures
Riley Bove, MD, FAAN	Dr. Bove has nothing to disclose.
Vilija Jokubaitis	Vilija Jokubaitis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Vilija Jokubaitis has received research support from National Health and Medical Research Council (NHMRC) of Australia. The institution of Vilija Jokubaitis has received research support from Multiple Sclerosis Australia. The institution of Vilija Jokubaitis has received research support from F.Hoffmann La-Roche.
Kerstin Hellwig	Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mylan . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Kerstin Hellwig has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Merck . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Novartis . Kerstin Hellwig has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche . The institution of Kerstin Hellwig has received research support from Roche . The institution of Kerstin Hellwig has received research support from Merck . The institution of Kerstin Hellwig has received research support from Biogen. The institution of Kerstin Hellwig has received research support from Genzyme . The institution of Kerstin Hellwig has received research support from Novartis . The institution of Kerstin Hellwig has received research support from BMS .

��ɫ��

��ɫ��